Talazoparib-13C,d4

Talazoparib-13C,d4

• UNSPSC Description: Talazoparib-13C,d4 is 13C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.
• Target Antigen: Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Others
• Field of Research: Others
• Purity: 99.30
• Solubility: DMSO : 25 mg/mL (ultrasonic;warming)
• Smiles: O=C1NN=C2C3=C1C=C(C=C3N[13C@@H]([C@H]2C4=NC=NN4C)C5=C(C([2H])=C(C([2H])=C5[2H])F)[2H])F
• Molecular Weight: 385.37
• References & Citations: [1]Wang B, et al. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59(1):335-57.|[2]Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19(18):5003-15.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported